- Gossamer Bio press release ( NASDAQ: GOSS ): Q3 GAAP EPS of -$0.65 misses by $0.01 .
- Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities as of September 30, 2022, were $304.4 million.
- Research and Development (R&D) Expenses: For the quarter ended September 30, 2022, R&D expenses were $44.5 million, compared to $43.2 million for the same period in 2021.
- General and Administrative (G&A) Expenses: For the quarter ended September 30, 2022, G&A expenses were $11.5 million, compared to $12.5 million for the same period in 2021.
For further details see:
Gossamer Bio GAAP EPS of -$0.65 misses by $0.01